Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03313778	TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors	Phase Phase 1	Date Added 2017-10-18	Location Arizona, United States California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japan United Kingdom	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs mRNA-4157, Pembrolizumab, Keytruda	Tags MSS/ MMRp
NCT ID NCT03310008	TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases	Phase Phase 1	Date Added 2017-10-16	Location Belgium	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs NKR-2 cells	Tags MSS/ MMRp
NCT ID NCT03297606	TitleCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)	Phase Phase 2	Date Added 2017-09-29	Location Canada	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03296137	TitleAdoptive Cell Therapy Across Cancer Diagnoses	Phase Phase 1/Phase 2	Date Added 2017-09-28	Location Denmark	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Autologous tumor-infiltrating lymphocytes, Cyclophosphamide, Fludara, Ipilimumab, Nivolumab, proleukin, Opdivo, Yervoy	Tags MSS/ MMRp
NCT ID NCT03290937	TitleUtomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2017-09-25	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, Irinotecan Hydrochloride, Utomilumab	Tags MSS/ MMRp
NCT ID NCT03289962	TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	Phase Phase 1	Date Added 2017-09-21	Location Arizona, United States California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States Belgium Canada Germany Netherlands Spain Sweden United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, Autogene cevumeran, Tecentriq	Tags MSS/ MMRp
NCT ID NCT03280511	TitleAdjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients	Phase Phase 2	Date Added 2017-09-12	Location Denmark	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs PIPAC	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03239145	TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor	Phase Phase 1	Date Added 2017-08-03	Location Massachusetts, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Pembrolizumab, Trebananib	Tags MSS/ MMRp
NCT ID NCT03223779	TitleStudy of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer	Phase Phase 1	Date Added 2017-07-21	Location Massachusetts, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03217747	TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	Phase Phase 1, Phase 2	Date Added 2017-07-14	Location Texas, United States	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio	Tags MSS/ MMRp

Showing 251 to 260 of 299 entries